The Technical Analyst
Syros Pharmaceuticals Inc [SYRS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Syros Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-5.94% $4.44
America/New_York / 19 apr 2024 @ 13:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 117.46 mill |
| EPS: | -5.81 |
| P/E: | -0.760 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 26.45 mill |
| Avg Daily Volume: | 0.220 mill |
| RATING 2024-04-19 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.760 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.13x |
| Company: PE -0.760 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.98 - 4.89 ( +/- 10.27%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | Roth David | Sell | 10 451 | Common Stock |
| 2024-03-31 | Stephens Kristin | Buy | 11 666 | Common Stock |
| 2024-04-01 | Stephens Kristin | Sell | 4 218 | Common Stock |
| 2024-03-31 | Stephens Kristin | Sell | 11 666 | Restricted Stock Units |
| 2024-03-31 | Stephens Kristin | Buy | 2 000 | Common Stock |
| INSIDER POWER |
|---|
| 55.16 |
| Last 100 transactions |
| Buy: 2 824 203 | Sell: 497 307 |
Forecast:
15:29 - $4.43
Live Trading Signals (every 1 min)
Forecast
1: 13:59 - $4.43
Forecast 2: 14:49 - $4.44
Forecast 3: 15:29 - $4.43
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.44 (-5.94% ) |
| Volume | 0.0757 mill |
| Avg. Vol. | 0.220 mill |
| % of Avg. Vol | 34.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SYRS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $7.07 | N/A | Active |
|---|
SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-09 07:00:00 - Press Release
Syros Receives Fast Track Designation From The Fda For Tamibarotene For The Treatment Of Newly Diagnosed Unfit Aml With Rara Gene Overexpression
Cambridge, mass.--(business wire)--syros pharmaceuticals (nasdaq:syrs), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the united states food and drug administration (fda) has granted fast track designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (aml) with rara overexpression as detected by an fda approved tes.
2024-04-02 16:30:00 - Press Release
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--syros pharmaceuticals (nasdaq:syrs), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit (rsu) award for 8,400 shares of syros common stock to one newly hired employee in connection with commencing employment with syros. this rsu was granted as a material inducement to employment in accordance with nasdaq listing rule 5635(c)(4). t.
2024-03-27 07:30:00 - Press Release
Syros Reports Fourth Quarter And Full Year 2023 Financial Results And Provides A Corporate Update
Cambridge, mass.--(business wire)--syros pharmaceuticals (nasdaq: syrs), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full year ended december 31, 2023 and provided a corporate update. “we are entering 2024 poised for a major transformation,” said conley chee, chief executive officer of syros. “we recently completed enrollment of the 190 patients necessary fo.
2024-03-25 07:00:00 - Press Release
Syros Announces Completion Of Enrollment Of 190 Patients Necessary To Support Primary Endpoint Analysis In Select-mds-1 Phase 3 Trial
Cambridge, mass.--(business wire)--syros pharmaceuticals (nasdaq:syrs), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the enrollment of 190 patients has been completed in the select-mds-1 phase 3 clinical trial evaluating tamibarotene in newly diagnosed higher-risk myelodysplastic syndrome (hr-mds) patients with rara gene overexpression. this initial cohort of 190 patients is necessary to su.
2024-03-20 07:00:00 - Press Release
Syros To Report Fourth Quarter And Full Year 2023 Financial Results On Wednesday, March 27, 2024
Cambridge, mass.--(business wire)--syros pharmaceuticals (nasdaq:syrs), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. et on wednesday, march 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update. to access the live conference call, please dial (888) 259-6580 (domestic) or (416) 76.
Latest News
2024-04-10 10:50:23 - Zacks Investment Research
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
2024-04-10 09:31:04 - Zacks Investment Research
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2024-04-02 08:01:59 - Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2024-01-31 16:00:00 - InvestorPlace
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
A company's size does not necessarily dictate the size of it's returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that will undoubtedly benefit your investments.
2024-01-19 11:46:06 - Zacks Investment Research
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.
2024-01-17 10:32:42 - Zacks Investment Research
Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why
Syros Pharmaceuticals, Inc. (SYRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2024-01-16 13:34:04 - Zacks Investment Research
What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
Syros Pharmaceuticals, Inc. (SYRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-01-16 11:22:44 - Zacks Investment Research
Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 199.3% in Syros Pharmaceuticals, Inc. (SYRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-01-11 10:34:42 - Zacks Investment Research
Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick
Syros Pharmaceuticals (SYRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2023-12-31 10:10:40 - 24/7 Wall Street
Here's What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, biotechs were in focus among the notable insider purchases.